P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLC
Balázs Halmos(Montefiore Medical Center), Enric Carcereny(Institut Català d'Ornitologia), Ross A. Soo(National University Cancer Institute, Singapore), M.K. Lee(Gwangju Institute of Science and Technology), Frank Griesinger(Carl von Ossietzky Universität Oldenburg), Pascal Foucher(CHU Dijon Bourgogne), Toyoaki Hida(Saitama International Medical Center), Barbara Melosky(BC Cancer Agency), Angela Märten(Boehringer Ingelheim (United States)), J. Cadranel(Sorbonne Université), E.H. Tan(National Cancer Centre Singapore), Maximilian J. Hochmair(Karl Landsteiner Society), Te‐Chun Hsia(China Medical University), E. Kim(Harvard University)
Cited by 1
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k